Erasca Inc. (ERAS)

$1.79

-0.05

(-2.72%)

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Erasca Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 85.3%

Performance

  • $1.76
    $1.87
    $1.79
    downward going graph

    1.68%

    Downside

    Day's Volatility :5.88%

    Upside

    4.28%

    downward going graph
  • $1.51
    $3.38
    $1.79
    downward going graph

    15.64%

    Downside

    52 Weeks Volatility :55.33%

    Upside

    47.04%

    downward going graph

Returns

PeriodErasca Inc.Sector (Health Care)Index (Russel 2000)
3 Months
3.37%
-0.7%
0.0%
6 Months
-21.37%
6.6%
0.0%
1 Year
-38.56%
3.7%
-1.5%
3 Years
-89.44%
14.0%
-21.8%

Highlights

Market Capitalization
292.4M
Book Value
$2.1
Earnings Per Share (EPS)
-0.83
Wall Street Target Price
7.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-19.44%
Return On Equity TTM
-34.33%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-137.8M
Diluted Eps TTM
-0.83
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.92
EPS Estimate Next Year
-0.99
EPS Estimate Current Quarter
-0.23
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Erasca Inc.(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
12
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 318.99%

Current $1.79
Target $7.50

Technicals Summary

Sell

Neutral

Buy

Erasca Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Erasca Inc.
Erasca Inc.
-10.24%
-21.37%
-38.56%
-89.44%
-89.44%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Erasca Inc.
Erasca Inc.
NA
NA
NA
-0.92
-0.34
-0.19
NA
2.1
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Erasca Inc.
Erasca Inc.
Buy
$292.4M
-89.44%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • ARCH VENTURE CORP

    7.32%
  • Armistice Capital, LLC

    5.36%
  • BlackRock Inc

    4.84%
  • Artal Group S A

    3.12%
  • Partner Fund Management LP

    2.60%
  • Vanguard Group Inc

    2.51%

Corporate Announcements

  • Erasca Inc. Earnings

    Erasca Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

our mission at erasca is embedded in our name: to erase cancer in patients by creating a new generation of oncology drugs that we hope will not just treat, but actually cure. energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. we have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals.

Organization
Erasca Inc.
Employees
126
CEO
Dr. Jonathan E. Lim M.D.
Industry
Services

FAQs